Clinical Protocol and Data Management (CPDM) responsibilities are fulfilled by the USC Norris Clinical Investigations Support Office (CISO). As the centralized clinical trials office for USC Norris, CISO manages, coordinates and provides a full range of services and helps to assure the conduct of high quality cancer clinical research in a safe, compliant and efficient manner. CISO assists investigators in protocol development and facilitates the review to activation process. It is also directly responsible for: 1) hiring, training and supervising clinical research staff, 2) quality assurance; 3) policies and procedures related to clinical trials conduct; 4) support and coordination of clinical research committees (PRMS, DSM, Quality Assurance); 5) metrics and reporting. The Medical Director of CISO is Anthony El-Khoueiry, MD, a highly experienced cancer clinical trialist. He is supported by Assistant Medical Director, Kevin Kelly, MD. CISO's Associate Director, Kay Johnson, RN, announced her retirement in 2014 after more than 20 years of service but continues as a consultant to ensure a smooth transition while a national search is on-going. Day to day activities are handled by two seasoned managers, the Assistant Director for Clinical Research Operations and Assistant Director for Regulatory Affairs. USC Norris has also engaged Huron Consulting to identify strategies for improvement and to help CISO respond to the continued growth and complexity of the clinical research program. CISO has successfully improved efficiency and effectiveness during the project period. Of particular note is USC's decision to implement OnCore enterprise-wide and to revamp the contracting and budgeting processes. Protocol turnaround has declined substantially while the number of IITs has increased. Accrual to interventional therapeutic trials has shown growth despite the increasing complexity of trial eligibility criteria. Other accomplishments include the establishment of a pre-PRMS design and feasibility consultation service, the development of standard operating procedures related to study conduct, the hiring of an education coordinator, and the national certification of research coordinators. In regards to clinical trials participation, USC Norris has continued to build on its successful strategies for the inclusion of minorities using a multi-prong approach. Hispanics and Asian Pacific Islanders represent the two largest minority communities in the USC Norris catchment area. In 2013, Hispanics represented 40.5% of new cancer cases at USC Norris hospitals and 44.8% of accrual to interventional therapeutic trials. Asian/Pacific Islanders represented 14.3% of new cancers at USC Norris hospitals and 11.3% of accrual to interventional therapeutic trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-44
Application #
9607935
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Ricker, Charité N; Koff, Rachel B; Qu, Chenxu et al. (2018) Patient communication of cancer genetic test results in a diverse population. Transl Behav Med 8:85-94
Valentin-Torres, Alice; Savarin, Carine; Barnett, Joslyn et al. (2018) Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation. J Neuroinflammation 15:121
Tobin, Jessica; Miller, Kimberly A; Baezconde-Garbanati, Lourdes et al. (2018) Acculturation, Mental Health, and Quality of Life among Hispanic Childhood Cancer Survivors: A Latent Class Analysis. Ethn Dis 28:55-60
Jayne, Jordanna G; Bensman, Timothy J; Schaal, Justin B et al. (2018) Rhesus ?-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol 58:310-319
Lee, Brian H; Stallcup, Michael R (2018) Different chromatin and DNA sequence characteristics define glucocorticoid receptor binding sites that are blocked or not blocked by coregulator Hic-5. PLoS One 13:e0196965
Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182
Woodham, Andrew W; Cheloha, Ross W; Ling, Jingjing et al. (2018) Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res 6:870-880
Matsusaka, S; Wu, A H; Cao, S et al. (2018) Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J 18:262-269
Vannini, Ivan; Fanini, Francesca; Fabbri, Muller (2018) Emerging roles of microRNAs in cancer. Curr Opin Genet Dev 48:128-133
Veyseh, Maedah; Ricker, Charite; Espenschied, Carin et al. (2018) Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Front Oncol 8:259

Showing the most recent 10 out of 842 publications